RadiSurf was established in 2015.
The goal of the company is to provide new solutions for adhesion, based on their knowledge regarding surface chemistry. The main challenge they are trying to solve is the binding of materials that are hard to bind using existing adhesives - sucs as plastics and metals. The company was sold during the summer of 2021, for DKK 100+ million.
The technology is ideal for a wide range of applications such as medico and Electronics.
VisBlue was founded in 2014 order to commercializes green energy storage with a patented vanadium redox flow battery.
The company is based on an invention made at the Department of Engineering relating to a system coupling a solar cell to a Redox Flow Battery.
The Technology Transfer Office invested in a patent application and supported the inventors in creating a company to further develop the technology.
Methyl Detect ApS was founded in 2016 with the intent to make cost-effective gene specific DNA methylation assays based upon MS-HRM technique available for researchers.
The company is based on an invention made at the Department of Biomedicine relating to a an optimised strategy for PCR primer design, that allow for more sensive methylation detection than what was previously possible.
The Technology Transfer Office invested in a patent application and supported the inventors in creating a company to further develop the technology.
VPCIR biosciences are primarily focused on food safety, but are also developing solutions within the medico area.
The primary product from the company is a fast and cheap to measure pathogenes. A patent application has been handed on the underlaying technology.
The company is a spin out from Aarhus University and The Chinese University of Hong Kong.
STipe Therapeutics is a spin out from Aarhus University founded in 2018. The company has developed First-in-Class drugs that exploits and strengthens the STING pathway response to combat cancer, by increasing the innate immune response within the tumor microenvironment. STipe received €20 mio in funding in 2019.
Draupnir Bio is a spin out from Department of Biomedicine at Aarhus University. The company's lead program focuses on the development of glycan mimetics for treatment of cardiovascular diseases. In 2019 Draupnir Bio received €30 mio. in Funding.
Muna Therapeutics is a spin out from Aarhus University, founded in 2020. The company is developing therapeutics to preserve brain function and enhance resilience to neurodegenerative diseases. In the Summer of 2021 Muna raised a series A funding round of 73 million USD.
